Rallybio (RLYB) Has a New Rating from J.P. Morgan

J.P. Morgan analyst Anupam Rama initiated coverage with a Buy rating on Rallybio (RLYBResearch Report) on December 9 and set a price target of $21.00. The company’s shares closed last Friday at $4.93.

According to TipRanks, Rama is a 3-star analyst with an average return of 2.1% and a 44.14% success rate. Rama covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics, Kodiak Sciences, and Elevation Oncology.

Currently, the analyst consensus on Rallybio is a Strong Buy with an average price target of $23.00, a 366.53% upside from current levels. In a report released on December 1, JMP Securities also reiterated a Buy rating on the stock with a $29.00 price target.

See today’s best-performing stocks on TipRanks >>

RLYB market cap is currently $182.6M and has a P/E ratio of -2.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Read More on RLYB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More